Slide 1: Future Proof Healthcare – Presentation Q1(22)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q1(22) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 1st quarter – Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 1st quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 179 employees & consultants at quarter end F
Slide 4: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis AMR Antimicrobial Resistance Leading cause of death in U.S. hospitals1) Has been presented as #1 hospitalization cost in the US with over $24bn “The biggest threat to mankind” yearly3) Rapid diagnostics would reduce Kills >500,000 peop
Slide 5: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood dra
Slide 6: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide up to 48 hours faster
Slide 7: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 8: Easy to use
Easy to use User friendly & 24/7 availability ASTar enables anyone at the lab to load sample anytime and enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 8
Slide 9: ASTar provides excellent performance
ASTar provides excellent performance Broad panel enabling actionable results Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antimicr
Slide 10: High throughput and flexible solution
High throughput and flexible solution High throughput & flexible Our ambition was the most user friendly and capable system Up to 12 patient samples in parallel = Fully automatic Semi automatic Consumables stored at room temp and a small insert at -20°C. Compatible with small and large (e.g. urine)
Slide 11: Key highlights first quarter
Key highlights first quarter The first commercial customer After a successful evaluation during 2021 a UK hospital became our first commercial customer. There is a strong interest for ASTar and the sales prospects funnel is growing Evaluation cycle is around 6 weeks to be followed by tender and quot
Slide 12: Key highlights first quarter
Key highlights first quarter ASTar is coming closer to the US market Q-linea’s ASTar classified as a breakthrough device by the FDA & we are in the final step of preparing the 510k submission 12 12 Source: Company information.
Slide 13: Key highlights after period end
Key highlights after period end ECCMID was a total success The interest in ASTar and other Q-linea products in developing was very strong Both the Q-linea and Thermo Fisher Scientific booth were fully occupied with demonstrations of ASTar A strong list of leads for both companies to follow up after
Slide 14: Key highlights after period end
Key highlights after period end ECCMID was a total success 14 14 Source: Company information.
Slide 15: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea Moving back to normal operation Finally, we are now all moving back to the new normal after the pandemic Future possible effects of the Corona pandemic Depending on the development of the pandemic the primary risk is reduced access to customers and to pe
Slide 16: Income statement first quarter
Income statement first quarter Net sales in the fourth quarter amounted to SEK 5.8 million (0.0). Goods that have been expensed in the first quarter amounted SEK -12.0 (-1.5) million. Operating result totalled SEK -71.8 million (-63.8). The company reported a loss after tax of SEK -71.9 million (-63
Slide 17: Balance sheet at the end of first quarter
Balance sheet at the end of first quarter Cash and cash equivalents amounted to SEK 15.4 million (15.1) Short-term investments in fixed-income funds SEK 106,1 million (91,2) and the current portion of non-current assets (listed bonds) SEK 40.6 million (59.7). Non-current assets, listed bonds SEK 128
Slide 18: Cash flow statement first quarter
Cash flow statement first quarter Cash flow from operating activities SEK -51.7 million (-56.1). Decrease in cash outflow from operating activities mainly due to favourable changes in the working capital compared to the same quarter last year. Cash flow from investing activities SEK 52.0 million (58
Slide 19: Thank you
Looking forward to an exciting continuation of 2022 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 19